Investment analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN – Get Rating) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the stock.
OGEN stock opened at $0.30 on Wednesday. Oragenics has a 52-week low of $0.22 and a 52-week high of $1.15. The company’s 50-day moving average price is $0.31. The company has a market capitalization of $34.80 million, a PE ratio of -2.14 and a beta of 0.12.
Oragenics (NYSE:OGEN – Get Rating) last released its quarterly earnings results on Thursday, March 24th. The company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $0.09 million for the quarter.
Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Further Reading
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- Should Silver Stocks Be A Part Of Your Portfolio?
- ABM Industries, A Clean Play For Dirty Economic Times
- This Still Isn’t A Buyable Bottom For Stocks
- Don’t Get Too Bullish On Lennar Even Though It’s A Good Buy
- Dividend-Paying Midstream Oil Companies That Could Help You The Mitigate Market Volatility
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
